Aml clinical trials germany

Maintenance therapy: 50 mg oral twice daily over one year. Outcome Measures. Primary Outcome Measures : Event-free Survival [ Time Frame: 8years ] To perform two predefined subgroup analyses in the age-groups years and years evaluating the impact of midostaurin given in combination with intensive induction, consolidation including allogeneic hematopoietic stem cell transplantation and single agent maintenance therapy on event-free survival EFS in adult patients with AML exhibiting a FLT3-ITD.

Quality of life assessed by the EORTC Quality of Life Core Questionnaire QLQ-C30 , supplemented by information on self-assessed concomitant diseases, late treatment effects, and demographics initially, in first CR, after one year,3 and 5 years after initial diagnosis.

Assessment of the relative impact of allogeneic HSCT analyzed as time-dependent variable on survival endpoints. Eligibility Criteria. Hormonal contraception is an inadequate method of birth control Men must use a latex condom during any sexual contact with women of childbearing potential, even if they have undergone a successful vasectomy while on therapy and for 5 months after the last dose of chemotherapy Signed written informed consent.

No consent for biobanking. Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials. More Information. Publications automatically indexed to this study by ClinicalTrials. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Epub Dec National Library of Medicine U. National Institutes of Health U. Department of Health and Human Services.

Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials. Marien Kliniken, St. Kliniken Bielefeld gem.

Klinikum St. Diakonie-Krankenhaus gemeinn. More Information. Additional Information: Website study alliance leukemia. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia? National Library of Medicine U. National Institutes of Health U. Department of Health and Human Services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.

Study Type :. Observational [Patient Registry]. Estimated Enrollment :. Study Start Date :. Estimated Primary Completion Date :. Estimated Study Completion Date :. Contact: Kai Neben, Prof. Contact: Thomas Geer, Dr. Contact: Walter Aulitzky, Prof. Contact: Markus Schaich, Prof. Contact: Martina Teichmann, Dr. Contact: Alexander Kiani, Prof. Contact: Christof Lamberti, PD. Contact: Stefan Krause, Prof. Clinical trials are under way for patients at every treatment stage and for patients in remission.

Today's standard treatments for cancer are based on earlier clinical trials. Genetics of Leukemia. The many chromosomal and genetic abnormalities in AML make treating this disease particularly challenging. There is a need to identify these genetic variations and customize treatment options based on the specific genetic characteristics of the leukemia cells. New gene sequencing techniques have revealed previously unknown mutations that may be involved in the development of AML.

This information will help researchers develop new targeted therapies, tailored to specific disease characteristics in each patient. New Drugs and Treatment Regimens. Researchers are working to develop safer and more effective treatments for AML. They are studying new drugs, as well as the use of different doses and delivery methods for existing drugs. During the last few decades, advances in the understanding of disease genetics have led to improvements in the overall survival of AML patients.

Researchers are also continuing to modify and reformulate traditional chemotherapy drugs and are evaluating combinations of chemotherapy drugs with newer targeted therapies to improve overall survival.

Treatment approaches being studied for use in AML patients include:. Click here to read more about clinical trials. A targeted therapy is a type of treatment that uses drugs or other substances to block the action of certain enzymes, proteins or other molecules involved in the growth and survival of cancer cells, while causing less harm to healthy cells.